# US 2023/0265201 A1 · Antibodies to cd70

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265201 A1
- Document ID: US20230265201A1
- Status: Published application
- Kind: A1
- Application number: 17/811,645
- Filed: 2022-07-11
- Published: 2023-08-24
- Earliest claimed: 2011-03-16
- Assignees: argenx BV
- Applicants: argenx BV
- Inventors: Karen SILENCE; Peter ULRICHTS; Johannes Joseph Wilhelmus DE HAARD; Torsten DREIER; Michael John Scott SAUNDERS; Harald WAJANT; Sofie Maria Elvire GABRIELS; Mahan MOSHIR
- Web page: https://patentgrep.com/patent/US20230265201A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.

## Claims

### Claim at position 1

1-49. (canceled)

### Claim 50

A host cell comprising:
(a) a first polynucleotide encoding a heavy chain variable domain (VH) comprising
(i) an HCDR3 region comprising the amino acid sequence set forth in SEQ ID NO: 50 (DAGYSNHVPIFDS);
(ii) an HCDR2 region comprising the amino acid sequence set forth in SEQ ID NO: 27 (DINNEGGTTYYADSVKG); and
(iii) an HCDR1 region comprising the amino acid sequence set forth in SEQ ID NO: 11 (VYYMN), and
(b) a second polynucleotide encoding a light chain variable domain (VL) comprising
(i) an LCDR3 region comprising the amino acid sequence set forth in SEQ ID NO: 160 (ALFISNPSVE),
(ii) an LCDR2 region comprising the amino acid sequence set forth in SEQ ID NO: 119 (NTNTRHS), and
(iii) an LCDR1 region comprising the amino acid sequence set forth in SEQ ID NO: 250 (GLKSGSVTSDNFPT).

### Claim 51 (depends on 50)

The host cell of claim 50, wherein
(a) the first polynucleotide encodes a VH comprising an amino acid sequence which is at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 223; and/or
(b) the second polynucleotide encodes a VL comprising an amino acid sequence which is at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 241.

### Claim 52 (depends on 50)

The host cell of claim 50, wherein:
(a) the first polynucleotide encodes a VH comprising the amino acid sequence set forth in SEQ ID NO: 223; and/or
(b) the second polynucleotide encodes a VL comprising the amino acid sequence set forth in SEQ ID NO: 241.

### Claim 53 (depends on 50)

The host cell of claim 50, wherein:
(a) the first polynucleotide encodes a human IgG1 IgG2, IgG3, or IgG4 heavy chain constant region; and/or
(b) the second polynucleotide encodes a human kappa light chain constant region or a human lambda light chain constant region.

### Claim 54 (depends on 50)

The host cell of claim 50, wherein:
(a) the first polynucleotide encodes an antibody heavy chain comprising the VH amino acid sequence set forth in SEQ ID NO: 223 and a human IgG1 heavy chain constant region; and
(b) the second polynucleotide encodes an antibody light chain comprising the VL amino acid sequence set forth in SEQ ID NO: 241 and a human lambda light chain constant region.

### Claim 55 (depends on 50)

The host cell of claim 50, wherein the first polynucleotide and the second polynucleotide are comprised within a single vector.

### Claim 56 (depends on 50)

The host cell of claim 50, wherein the first polynucleotide and the second polynucleotide are comprised within separate vectors.

### Claim 57 (depends on 50)

The host cell of claim 50, wherein the host cell is a Chinese hamster ovary cell.

### Claim 58 (depends on 54)

The host cell of claim 54, wherein the host cell is a Chinese hamster ovary cell.

### Claim 59 (depends on 50)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 50 so that the polynucleotides are expressed and the antibody is produced.

### Claim 60 (depends on 59)

The method of claim 59, wherein the antibody is non-fucosylated.

### Claim 61 (depends on 52)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 52 so that the polynucleotides are expressed and the antibody is produced.

### Claim 62 (depends on 53)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 53 so that the polynucleotides are expressed and the antibody is produced.

### Claim 63 (depends on 54)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 54 so that the polynucleotides are expressed and the antibody is produced.

### Claim 64 (depends on 63)

The method of claim 63, wherein the antibody is non-fucosylated.

### Claim 65 (depends on 57)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 57 so that the polynucleotides are expressed and the antibody is produced.

### Claim 66 (depends on 65)

The method of claim 65, wherein the antibody is non-fucosylated.

### Claim 67 (depends on 58)

A method of producing an antibody that specifically binds to human CD70 comprising culturing the host cell of claim 58 so that the polynucleotides are expressed and the antibody is produced.

### Claim 68 (depends on 67)

The method of claim 67, wherein the antibody is non-fucosylated.

### Claim 69

A vector comprising:
(a) a first polynucleotide encoding a heavy chain variable domain (VH) comprising
(i) an HCDR3 region comprising the amino acid sequence set forth in SEQ ID NO: 50 (DAGYSNHVPIFDS);
(ii) an HCDR2 region comprising the amino acid sequence set forth in SEQ ID NO: 27 (DINNEGGTTYYADSVKG); and
(iii) an HCDR1 region comprising the amino acid sequence set forth in SEQ ID NO: 11 (VYYMN), and
(b) a second polynucleotide encoding a light chain variable domain (VL) comprising
(i) an LCDR3 region comprising the amino acid sequence set forth in SEQ ID NO: 160 (ALFISNPSVE),
(ii) an LCDR2 region comprising the amino acid sequence set forth in SEQ ID NO: 119 (NTNTRHS), and
(iii) an LCDR1 region comprising the amino acid sequence set forth in SEQ ID NO: 250 (GLKSGSVTSDNFPT).
